Rather, its an eating approach designed to work alongside GLP-1 medications such as Ozempic, Wegovy, and Mounjaro
GLP-1 receptors exist on vascular endothelial cells, where activation can improve blood vessel function and reduce inflammation
About this article Cite this article Rizzo, F., Riboldi, G., Salani, S
Moreover, the median follow-up in the primary analyses was 4.5 years for DPP4 inhibitors with 25% of the patients (i.e
Projections suggest an escalating trend, with the prevalence anticipated to reach 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045
OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing "substantial reductions in body weight" after 48 weeks of treatment